• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by British American Tobacco Industries p.l.c.

    8/28/25 6:26:52 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BTI alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    British American Tobacco p.l.c.

    (Name of Issuer)


    Ordinary Shares

    (Title of Class of Securities)


    GB0002875804

    (CUSIP Number)


    Samira Rajaram
    30 Baker Street, Rosebank
    Johannesburg, T3, 2196
    27114154465

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    08/26/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    GB0002875804


    1 Name of reporting person

    STANDARD BANK OF SOUTH AFRICA LTD
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF, OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    SOUTH AFRICA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    132,926,664.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    132,926,664.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    132,926,664.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    6.1 %
    14Type of Reporting Person (See Instructions)

    BD, IA, IV, BK

    Comment for Type of Reporting Person:
    Standard Bank is a licensed bank and Financial Service provider in South Africa. SBG Securities (Pty) Ltd is a subsidiary of the Standard Bank Group and is the equity broker for the group and has a membership with the Johannesburg Stock Exchange (JSE) and A2X exchange in South Africa.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Ordinary Shares
    (b)Name of Issuer:

    British American Tobacco p.l.c.
    (c)Address of Issuer's Principal Executive Offices:

    GLOBE HOUSE, 4 TEMPLE PLACE, LONDON, UNITED KINGDOM , SW1V 1PN.
    Item 1 Comment:
    Standard Bank is a licensed bank and Financial Service provider in South Africa. SBG Securities Pty Ltd is a subsidiary of the Standard Bank Group and is the equity broker for the group and has a membership with the Johannesburg Stock Exchange and A2X exchange in South Africa. As part of the Group and subsidiaries trading. As part of the Groups trading, investment and hedging strategies, it may hold equity positions from time to time.
    Item 2.Identity and Background
    (a)
    Name: Standard Bank Group Entity Type: Publicly listed Company
    (b)
    Address: 30 Baker Street, Rosebank, Johannesburg 2196
    (c)
    Standard Bank is a licensed bank and Financial Service provider in South Africa. SBG Securities Pty Ltd is a subsidiary of the Standard Bank Group and is the equity broker for the group and has a membership with the Johannesburg Stock Exchange and A2X exchange in South Africa. As part of the Groups trading, investment and hedging strategies, it may hold equity positions from time to time.
    (d)
    No
    (e)
    No
    (f)
    South Africa
    Item 3.Source and Amount of Funds or Other Consideration
     
    Standard Bank is a licensed bank and Financial Service provider in South Africa. SBG Securities Pty Ltd is a subsidiary of the Standard Bank Group and is the equity broker for the group and has a membership with the Johannesburg Stock Exchange and A2X exchange in South Africa. As part of the Groups trading, investment and hedging strategies, it may hold equity positions from time to time.
    Item 4.Purpose of Transaction
     
    Standard Bank is a licensed bank and Financial Service provider in South Africa. SBG Securities Pty Ltd is a subsidiary of the Standard Bank Group and is the equity broker for the group and has a membership with the Johannesburg Stock Exchange and A2X exchange in South Africa. As part of the Groups trading, investment and hedging strategies, it may hold equity positions from time to time.
    Item 5.Interest in Securities of the Issuer
    (a)
    Aggregate Number: 132,926,664 Percentage: 6.1%
    (b)
    Number of shares = 132,926,664
    (c)
    Standard Bank is a licensed bank and Financial Service provider in South Africa. SBG Securities Pty Ltd is a subsidiary of the Standard Bank Group and is the equity broker for the group and has a membership with the Johannesburg Stock Exchange and A2X exchange in South Africa. As part of the Groups trading, investment and hedging strategies, it may hold equity positions from time to time.
    (d)
    Standard Bank is a licensed bank and Financial Service provider in South Africa and is a public company listed on the Johannesburg Stock Exchange.
    (e)
    N/A
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    Standard Bank is a licensed bank and Financial Service provider in South Africa. SBG Securities Pty Ltd is a subsidiary of the Standard Bank Group and is the equity broker for the group and has a membership with the Johannesburg Stock Exchange and A2X exchange in South Africa. As part of the Groups trading, investment and hedging strategies, it may hold equity positions from time to time.
    Item 7.Material to be Filed as Exhibits.
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    STANDARD BANK OF SOUTH AFRICA LTD
     
    Signature:S Rajaram
    Name/Title:Samira Rajaram - Compliance Officer
    Date:08/28/2025
    Get the next $BTI alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BTI

    DatePrice TargetRatingAnalyst
    9/8/2025$62.00Hold → Buy
    Argus
    9/2/2025Sector Perform → Underperform
    RBC Capital Mkts
    7/9/2025Buy
    Jefferies
    4/30/2025Buy
    BofA Securities
    1/27/2025Neutral → Buy
    UBS
    10/3/2024$33.00Overweight → Underweight
    Morgan Stanley
    1/23/2024Neutral
    UBS
    11/1/2023$38.00Overweight
    Morgan Stanley
    More analyst ratings

    $BTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    British American Tobacco upgraded by Argus with a new price target

    Argus upgraded British American Tobacco from Hold to Buy and set a new price target of $62.00

    9/8/25 8:36:41 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    British American Tobacco downgraded by RBC Capital Mkts

    RBC Capital Mkts downgraded British American Tobacco from Sector Perform to Underperform

    9/2/25 8:32:33 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    Jefferies resumed coverage on British American Tobacco

    Jefferies resumed coverage of British American Tobacco with a rating of Buy

    7/9/25 8:26:14 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTI
    SEC Filings

    View All

    SEC Form SCHEDULE 13D filed by British American Tobacco Industries p.l.c.

    SCHEDULE 13D - British American Tobacco p.l.c. (0001303523) (Subject)

    9/3/25 10:10:49 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by British American Tobacco Industries p.l.c.

    6-K - British American Tobacco p.l.c. (0001303523) (Filer)

    9/2/25 7:43:10 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SCHEDULE 13D filed by British American Tobacco Industries p.l.c.

    SCHEDULE 13D - British American Tobacco p.l.c. (0001303523) (Subject)

    8/28/25 6:26:52 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Charlotte's Web Reports 2024 First Quarter Financial Results

    LOUISVILLE, Colo., May 8, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full-spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2024. "The first quarter of 2024 started slowly in terms of sales volume. This is being addressed with solid progress in our 'True North' turnaround initiatives," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "For example, our legacy e-commerce platform limits our ability to be agile

    5/8/24 7:07:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    British American Tobacco p.l.c investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises British American Tobacco p.l.c (NYSE:BTI) investors that a lawsuit was filed on behalf of investors that purchased BTI securities between February 9, 2023 and December 6, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing cla

    1/24/24 6:21:08 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    Organigram Announces C$124.6 Million Investment from BAT and Creation of "Jupiter" Strategic Investment Pool

    Organigram and BAT deepen partnership through C$124.6 million investment with 38.7 million shares to be issued over three tranches Organigram to use C$83.1 million of the investment to create "Jupiter," a strategic investment pool designed to expand Organigram's geographic footprint and capitalize on emerging growth opportunities C$41.5 million of the investment will be used for general corporate purposes Investment enhances strategic Product Development Collaboration between BAT and Organigram, which focuses on cutting-edge R&D and product innovation BAT to increase voting Common Share ownership position to 30% and overall equity interest to 45% (including non-voting Class A P

    11/6/23 6:00:00 AM ET
    $BTI
    $OGI
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $BTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Bt De Investments Inc.

    3 - British American Tobacco p.l.c. (0001303523) (Reporting)

    11/23/22 4:29:54 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTI
    Leadership Updates

    Live Leadership Updates

    View All

    British American Tobacco p.l.c investors: Please contact the Portnoy Law Firm to recover your losses; March 25, 2024 deadline

    Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises British American Tobacco p.l.c (NYSE:BTI) investors that a lawsuit was filed on behalf of investors that purchased BTI securities between February 9, 2023 and December 6, 2023, inclusive (the "Class Period"). Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors' options for pursuing cla

    1/24/24 6:21:08 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    Charlotte's Web Announces Appointment of Bill Morachnick as Chief Executive Officer

    Provides Update on Majority Voting Policy Process LOUISVILLE, Colo., Sept. 13, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF) Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company") is pleased to announce the appointment of William (Bill) Morachnick who has joined the Company as its Chief Executive Officer. Mr. Morachnick has also been appointed to the Company's Board of Directors as a non-independent director. He replaces CEO Jacques Tortoroli who has elected to resign from his roles at Charlotte's Web.  CWEB) (OTCQX:CWBHF):. The World's Most Trusted Hemp Extract and Official CBD of Major League Baseball (MLB). (C

    9/13/23 7:07:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    GREENBUTTS APPPOINTS FORMER BIG TOBACCO EXECUTIVE AS CHIEF STRATEGY OFFICER

    SAN DIEGO, Calif., June 22, 2022 /PRNewswire/ - Greenbutts, LLC (the "Company" or "Greenbutts") is pleased to announce the appointment of Luis Sanches as the Company's Chief Strategy Officer effective immediately. Luis is a Senior Corporate Executive with more than 30 years of international, cross functional and cross-cultural experience responsible for managing business teams, supporting growth, and leading transformations across multiple geographies such as Australasia, North and South America, and Europe. He was previously the Senior Vice President of R&D for Reynolds Ameri

    6/22/22 2:34:00 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTI
    Financials

    Live finance-specific insights

    View All

    Charlotte's Web Reports 2024 First Quarter Financial Results

    LOUISVILLE, Colo., May 8, 2024 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full-spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2024. "The first quarter of 2024 started slowly in terms of sales volume. This is being addressed with solid progress in our 'True North' turnaround initiatives," said Bill Morachnick, Chief Executive Officer of Charlotte's Web. "For example, our legacy e-commerce platform limits our ability to be agile

    5/8/24 7:07:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    Charlotte's Web Reports 2023 Second Quarter Financial Results

    Encouraging CBD regulatory progress in CongressNet revenue of $16.0M vs. $18.9M YoYCash increased to $61.7M LOUISVILLE, Colo., Aug. 10, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full spectrum hemp extract wellness products, today reported financial results for the second quarter ended June 30, 2023.  Regulatory Update During the second quarter, the U.S. Food and Drug Administration ("FDA") committed to "work at speed" with Congress to resolve a regulatory pathway for hemp-derived CBD.

    8/10/23 7:33:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    Charlotte's Web Reports 2023 First Quarter Financial Results

    Net cash of $61MNet revenue of $17M decreased 12.1% YoY14% YoY reduction in operating expenses LOUISVILLE, Colo., May 12, 2023 /PRNewswire/ - (TSX:CWEB) (OTCQX:CWBHF), Charlotte's Web Holdings, Inc. ("Charlotte's Web" or the "Company"), the market leader in full spectrum hemp extract wellness products, today reported financial results for the first quarter ended March 31, 2023. "In the first quarter, we maintained prudent cost controls to balance softness in the CBD category due to the unregulated environment. We successfully reduced operating expenses by 14% on a year-over-ye

    5/12/23 7:05:00 AM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    $BTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

    SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

    2/9/24 6:03:23 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

    SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

    2/9/24 5:46:32 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form SC 13G/A filed by British American Tobacco Industries p.l.c. (Amendment)

    SC 13G/A - British American Tobacco p.l.c. (0001303523) (Subject)

    1/26/24 4:56:06 PM ET
    $BTI
    Medicinal Chemicals and Botanical Products
    Health Care